Onx­eo shares blitzed af­ter PhI­II liv­er can­cer study flops

Shares of Paris-based Onx­eo were blitzed af­ter the biotech re­port­ed that its Phase III can­cer study had failed.

Study­ing Li­vatag (dox­oru­bicine Trans­drug) in com­par­i­son with best stan­dard of care, re­searchers said that they could see no sig­nif­i­cant dif­fer­ence on sur­vival scores among pa­tients with in­op­er­a­ble liv­er can­cer who were ei­ther in­tol­er­ant to so­rafenib or had pro­gressed on so­rafenib.

Onx­eo tried hard to ex­plain away the trou­ble, but its stock {Eu­ronext Paris:ONX­EO} plunged by more than half as in­vestors bowed out of a messy sit­u­a­tion.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER